Xoft medical director wins award for cancer research
Xoft Consulting Medical Director, Mark Carol, MD, has received the Ira Sohn Conference Foundation Prize in Pediatric Oncology for his research focused on novel approaches for using KV x-ray-based radiation therapy to treat cancer patients.
According to Carol, Xoft’s Axxent Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, was the inspiration for his work that was recognized by the Gotham Prize for Cancer Research.
"After having spent more than 20 years in radiation oncology, I believe that without significant and dramatic new approaches to solve ongoing problems in cancer treatment, we will only see incremental advances to patient care,” said Carol. “My first exposure to Xoft’s internally delivered KV X-rays encouraged me to explore novel approaches to KV radiation delivery that might lead to such fundamental breakthroughs in cancer research and treatment. The work recognized by the Gotham Prize involves a technique for delivering external beam KV X-rays in such a way that they can attain therapeutic levels deeper in tissue, and selectively in cancer cells versus normal cells, than has been previously possible."
The Ira Sohn Research Conference Foundation - which was founded in 1995 in honor of Ira Sohn, a successful Wall Street trader who died of cancer at the age of 29 - provides support for both prizes.
According to Carol, Xoft’s Axxent Electronic Brachytherapy System, a proprietary technology platform designed to deliver localized, non-radioactive, isotope-free radiation treatment in minimally-shielded clinical settings, was the inspiration for his work that was recognized by the Gotham Prize for Cancer Research.
"After having spent more than 20 years in radiation oncology, I believe that without significant and dramatic new approaches to solve ongoing problems in cancer treatment, we will only see incremental advances to patient care,” said Carol. “My first exposure to Xoft’s internally delivered KV X-rays encouraged me to explore novel approaches to KV radiation delivery that might lead to such fundamental breakthroughs in cancer research and treatment. The work recognized by the Gotham Prize involves a technique for delivering external beam KV X-rays in such a way that they can attain therapeutic levels deeper in tissue, and selectively in cancer cells versus normal cells, than has been previously possible."
The Ira Sohn Research Conference Foundation - which was founded in 1995 in honor of Ira Sohn, a successful Wall Street trader who died of cancer at the age of 29 - provides support for both prizes.